Radiolanthanides in endoradiotherapy: an overview

Separation of terbium as a first step towards high purity terbium-161 for medical applications

Terbium-161 is a medical radiolanthanide that has a beta decay energy and half-life similar to that of lutetium-177, which makes it a promising alternative for therapeutic purposes. The production route using an enriched gadolinium-160 target necessitates the purification of terbium-161 from the untransmuted target material as well as from its stable decay product, dysprosium-161. The separation of neighbouring lanthanides is challenging due to their similar chemical properties and prominent trivalent oxidation states. In this work, the aim is to change the oxidation state of terbium, resulting in the altering of chemical properties that ease the intragroup separation. To this end, a novel separation method is investigated, involving the electrochemical oxidation of terbium (3+) to terbium (4+) followed by anion exchange chromatography. The electrolysis conditions are set to the highest achievable conversion rate, followed by a dilution step during which the pH and electrolyte concentration are slightly lowered to obtain conditions that are compatible with the separation method. XAS analysis is done to characterize the carbonato complex of both oxidation states and to further elucidate the separation mechanism. The results show that the separation approach of combining electrochemical oxidation with anion exchange chromatography is promising for the purification of 161Tb for medical use.

Experimental study of α-particle induced reactions on natural erbium for the production of Auger-emitters 167Tm, 165Er and 169Yb

The cross sections for nuclear reactions ^natEr(α,x) were measured in the energy range 60 → 10 MeV using the stacked-foil technique. The experiments were carried out in a wider energy range in comparison with previous works. The results are consistent with other studies and modeling using TENDL-2019. The ¹⁶⁷Tm yield was 5.4 MBq/μAh in the range 60 → 30 MeV, and the main long-lived impurity is ¹⁶⁸Tm (0.78% in terms of activity). The ¹⁶⁵Tm yield is 4.6 MBq/μAh (60 → 40 MeV). ¹⁶⁹Yb is formed with a yield of 1.0 MBq/μAh in the energy range 60 → 20 MeV.

Production of Mass-Separated Erbium-169 Towards the First Preclinical in vitro Investigations

The β--particle-emitting erbium-169 is a potential radionuclide toward therapy of metastasized cancer diseases. It can be produced in nuclear research reactors, irradiating isotopically-enriched 168Er2O3. This path, however, is not suitable for receptor-targeted radionuclide therapy, where high specific molar activities are required. In this study, an electromagnetic isotope separation technique was applied after neutron irradiation to boost the specific activity by separating 169Er from 168Er targets. The separation efficiency increased up to 0.5% using resonant laser ionization. A subsequent chemical purification process was developed as well as activity standardization of the radionuclidically pure 169Er. The quality of the 169Er product permitted radiolabeling and pre-clinical studies. A preliminary in vitro experiment was accomplished, using a 169Er-PSMA-617, to show the potential of 169Er to reduce tumor cell viability.

Chiral Lanthanide Complexes with l- and d-Alanine: An X-ray and Vibrational Circular Dichroism Study

A whole series of [Ln(H2O)4(Ala)2]26+ dimeric cationic lanthanide complexes with both L- and D-alanine enantiomers was synthesized. The single-crystal X-ray diffraction at 100 and 292 K shows the formation of two types of dimers (I and II) in crystals. Between the dimer centers, the alanine molecules behave as bridging (μ2-O,O'-) and chelating bridging (μ2-O,O,O'-) ligands. The first type of bridge is present in dimers I, while both bridge forms can be observed in dimers II. The IR and vibrational circular dichroism (VCD) spectra of all L- and D-alanine complexes were registered in the 1750-1250 cm-1 range as KBr pellets. Despite all the studied complexes are exhibiting similar crystal structures, the spectra reveal correlations or trends with the Ln-O1 distances which exemplify the lanthanide contraction effect in the IR spectra. This is especially true for the positions and intensities of some IR bands. Unexpectedly, the ν(C=O) VCD bands are quite intense and their composed shapes reveal the inequivalence of the C=O vibrators in the unit cell which vary with the lanthanide. Unlike in the IR spectra, the ν(C=O) VCD band positions are only weakly correlated with the change of Ln and the VCD intensities at most show some trends. Nevertheless, this is the first observation of the lanthanide contraction effect in the VCD spectra. Generally, for the heavier lanthanides (Ln: Dy-Lu), the VCD band maxima are very close to each other and the mirror reflection of the band of two enantiomers is usually better than that of the lighter Lns. DFT calculations show that the higher the multiplicity the higher the stability of the system. Actually, the molecular geometry in crystals (at 100 K) is well predicted based on the highest-spin structures. Also, the simulated IR and VCD spectra strongly depend on the Ln electron configuration but the best overall agreement was reached for the Lu complex, which is the only system with a fully filled f-shell.

A Step-by-Step Guide for the Novel Radiometal Production for Medical Applications: Case Studies with 68Ga, 44Sc, 177Lu and 161Tb

The production of novel radionuclides is the first step towards the development of new effective radiopharmaceuticals, and the quality thereof directly affects the preclinical and clinical phases. In this review, novel radiometal production for medical applications is briefly elucidated. The production status of the imaging nuclide 44Sc and the therapeutic β--emitter nuclide 161Tb are compared to their more established counterparts, 68Ga and 177Lu according to their targetry, irradiation process, radiochemistry, and quality control aspects. The detailed discussion of these significant issues will help towards the future introduction of these promising radionuclides into drug manufacture for clinical application under Good Manufacturing Practice (GMP).

Separation of radioisotopes of terbium from a europium target irradiated by 27 MeV α-particles

A method for obtaining 156, 155, 154m2, 154, 153Tb radiotracers by the irradiation of a europium oxide target of natural isotopic composition by 27 MeV α-particles is proposed. Terbium can be efficiently separated from bulk of europium by the reduction of the latter by zinc in an acidic solution and precipitation as EuSO4. The optimum Zn/Eu3+ and (NH4)2SO4/Eu3+ molar ratios are 20 and 3, respectively. Terbium is additionally purified from europium and gadolinium by extraction chromatography using LN Resin. It is demonstrated that optimum separation is attained in 0.6 M HNO3. The Tb/Eu separation coefficient was ~5·105. The yield of terbium was about 90%. Time of all steps was 1.5–2 h. The proposed procedure makes it possible to obtain no carrier added terbium radiotracers.

Activation cross sections of proton and deuteron induced nuclear reactions on holmium and erbium, related to the production of (161)Er and (160)Er medical isotopes

Experimental excitation functions for long-lived products in proton induced reactions were measured with the activation method in the 37-65MeV energy range on natural holmium. Stacked foil irradiation technique and high resolution gamma spectrometry were used in order to measure cross-section data for the production of (161)Er, (160)Er and (1)(59,157)Dy. For comparison of the production routes of medically related (161)Er and (160)Er radioisotopes new experimental cross section data were deduced for the (162)Er(p,x)(161,160)Er and (162)Er(d,x)(161,160)Er reactions by re-evaluating gamma-ray spectra from earlier measurements. No earlier data were found in the literature for these reactions. The experimental data are compared with results of TALYS theoretical code reported in TENDL-2015.

The present and future of medical radionuclide production

Medical radionuclide production technology is well established. Both reactors and cyclotrons are utilized for production; the positron emitters, however, are produced exclusively using cyclotrons. A brief survey of the production methods of most commonly used diagnostic and therapeutic radionuclides is given. The emerging radionuclides are considered in more detail. They comprise novel positron emitters and therapeutic radionuclides emitting low-range electrons and α-particles. The possible alternative production routes of a few established radionuclides, like 68Ga and 99mTc, are discussed. The status of standardisation of production data of the commonly used as well as of some emerging radionuclides is briefly mentioned. Some notions on anticipated future trends in the production and application of radionuclides are considered.

Inorganic chemistry in nuclear imaging and radiotherapy: current and future directions

Radiometals play an important role in diagnostic and therapeutic radiopharmaceuticals. This field of radiochemistry is multidisciplinary, involving radiometal production, separation of the radiometal from its target, chelate design for complexing the radiometal in a biologically stable environment, specific targeting of the radiometal to its in vivo site, and nuclear imaging and/or radiotherapy applications of the resultant radiopharmaceutical. The critical importance of inorganic chemistry in the design and application of radiometal-containing imaging and therapy agents is described from a historical perspective to future directions.

Investigation on the production and isolation of 149,150,151Tb from 12C irradiated natural praseodymium target

Short lived α-emitting radionuclides have enormous potential to be used in the targeted therapy. 149Tb (4.118 h) is among the few α-emitting radionuclides which are projected for human clinical use. Therefore, direct production of 149Tb was aimed from the 12C induced reaction on natural praseodymium target of 15 mg∕cm2 thickness at 71.5 MeV incident beam energy. No-carrier-added (nca) 149,150,151Tb radionuclides were produced in the target matrix along with 149Gd, which is also the decay product of 149Tb, with relatively high yield of 149Tb. An efficient radiochemical separation method was developed to separate nca 149–151Tb from bulk praseodymium and coproduced Gd by liquid–liquid extraction (LLX) using aqueous HCl and liquid cation extracting agent di-(2-ethylhexyl)phosphoric acid (HDEHP) dissolved in cyclohexane. Quantitative extraction of nca 149–151Tb was achieved from bulk target with a high separation factor of 4.7×105.

Lanthanide dota-like complexes containing a picolinate pendant: structural entry for the design of Ln(III)-based luminescent probes

In this contribution we present two ligands based on a do3a platform containing a picolinate group attached to the fourth nitrogen atom of the cyclen unit, which are designed for stable lanthanide complexation in aqueous solutions. Potentiometric measurements reveal that the thermodynamic stability of the complexes is very high (log K = 21.2-23.5), being comparable to that of the dota analogues. Luminescence lifetime measurements performed on solutions of the Eu(III) and Tb(III) complexes indicate that the complexes are nine coordinate with no inner-sphere water molecules. A combination of density functional theory (DFT) calculations and NMR measurements shows that for the complexes of the heaviest lanthanides there is a major isomer in solution consisting of the enantiomeric pair Λ(δδδδ) and Δ(λλλλ), which provides square antiprismatic coordination (SAP) around the metal ion. Analysis of the Yb(III)-induced paramagnetic shifts unambiguously confirms that these complexes have SAP coordination in aqueous solution. For the light lanthanide ions however both the SAP and twisted-square antiprismatic (TSAP) isomers are present in solution. Inversion of the cyclen ring appears to be the rate-determining step for the Λ(δδδδ) ↔ Δ(λλλλ) enantiomerization process observed in the Lu(III) complexes. The energy barriers obtained from NMR measurements for this dynamic process are in excellent agreement with those predicted by DFT calculations. The energy barriers calculated for the arm-rotation process are considerably lower than those obtained for the ring-inversion path. Kinetic studies show that replacement of an acetate arm of dota by a picolinate pendant results in a 3-fold increase in the formation rate of the corresponding Eu(III) complexes and a significant increase of the rates of acid-catalyzed dissociation of the complexes. However, these rates are 1-2 orders of magnitude lower than those of do3a analogues, which shows that the complexes reported herein are remarkably inert with respect to metal ion dissociation.

Molecular recognition of sialic acid by lanthanide(III) complexes through cooperative two-site binding

Herein we report two new ligands, 1,4,7-tris(carboxymethyl)-10-[2-(dihydroxyboranyl)benzyl]-1,4,7,10-tetraazacyclododecane (L(1)) and 1,4,7-tris(carboxymethyl)-10-[3-(dihydroxyboranyl)benzyl]-1,4,7,10-tetraazacyclododecane (L(2)), which contain a phenylboronic acid (PBA) function and a 1,4,7,10-tetraazacyclododecane-1,4,7-triacetate cage for complexation of lanthanide ions in an aqueous solution. The pK(a) of the PBA function amounts to 4.6 in [Gd(L(1))] and 8.9 in [Gd(L(2))], with the value of the L(2) analogue being very similar to that of PBA (8.8). These results are explained by the coordination of the PBA function of L(1) to the Gd(III) ion, which results in a dramatic lowering of its pK(a). As a consequence, [Gd(L(1))] does not bind to saccharides at physiological pH. The nuclear magnetic relaxation dispersion profiles recorded for [Gd(L(1))] and [Gd(L(2))] confirm that the phenylboronate function is coordinated to the metal ion in the L(1) derivative, which results in a q = 0 complex. The interaction of the [Gd(L(2))] complex with 5-acetylneuraminic acid (Neu5Ac) and 2-alpha-O-methyl-5-acetylneuraminic acid (MeNeu5Ac) has been investigated by means of spectrophotometric titrations in an aqueous solution (pH 7.4, 0.1 M 3-(N-morpholino)propanesulfonic acid buffer). Furthermore, we have also investigated the binding of these receptors with competing monosaccharides such as D-(+)-glucose, D-fructose, D-mannose, D-galactose, methyl alpha-D-galactoside, and methyl alpha-D-mannoside. The binding constants obtained indicate an important selectivity of [Gd(L(2))] for Neu5Ac (K(eq) = 151) over D-(+)-glucose (K(eq) = 12.3), D-mannose (K(eq) = 21.9), and D-galactose (K(eq) = 24.5). Furthermore, a very weak binding affinity was observed in the case of methyl alpha-D-galactoside and methyl alpha-D-mannoside. An 8-fold increase of the binding constant of [Gd(L(2))] with Neu5Ac is observed when compared to that of PBA determined under the same conditions (K(eq) = 19). (13)C NMR spectroscopy and density functional theory calculations performed at the B3LYP/6-31G(d) level show that this is due to a cooperative two-site binding of Neu5Ac through (1) ester formation by interaction on the PBA function of the receptor and (2) coordination of the carboxylate group of Neu5Ac to the Gd(III) ion. The emission lifetime of the (5)D(4) level of Tb(III) in [Tb(L(2))] increases upon Neu5Ac binding, in line with the displacement of inner-sphere water molecules due to coordination of Neu5Ac to the metal ion.

Radiosynthesis of new [90Y]-DOTA-based maleimide reagents suitable for the prelabeling of thiol-bearing L-oligonucleotides and peptides

We describe the radiosynthesis of two new [(90)Y]-DOTA-based maleimide reagents, suitable for the mild radiolabeling of L-RNAs and peptides modified with thiol-bearing linkers. The synthesis procedure of both maleimide-bearing (90)Y complexes, [{(2S)-2-[4-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)benzyl]-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrayl}tetraacetato][(90)Y]yttrate(1-)([(90)Y]3) and [{(2S)-2-(4-{[4-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)butanoyl]amino}benzyl)-1,4,7,10-tetraaza-cyclododecane-1,4,7,10-tetrayl]tetraacetato}[(90)Y]yttrate(1-)([(90)Y]4), was optimized in terms of an easy purification method via solid-phase extraction (SPE). Application as well as reactivity of both maleimide reagents were initially evaluated by the prelabeling of glutathione (GSH) and a thiol-modified 12mer L-RNA as model substances. In comparison to the N-aryl maleimide-bearing complex [(90)Y]3, N-alkyl maleimide-bearing complex [(90)Y]4 showed an increased hydrolytic stability at pH > or = 7. A slightly higher reactivity was found for [(90)Y]3 by prelabeling of 0.1 and 1 microg glutathione, respectively, in phosphate buffer (pH 7.2) at room temperature. In terms of very high radiochemical yields, the direct radiolabeling of DOTA-L-RNA conjugate with [(90)Y]YCl(3) proved to be more suitable than the prelabeling of the thiol-modified 12mer L-RNA derivative with [(90)Y]4.